Laboratory studies of mice and human cells found that a protein called Metastasis suppressor 1 (Mtss1) is downregulated in hematopoietic and progenitor cells when chronic myeloid leukemia is present. Mtss1 levels are restored when complete remission is achieved, suggesting the pathway might represent a new therapeutic target.
Hematologic Cancer Targets
The FDA granted approval to ofatumumab for the treatment of patients with recurrent or progressive chronic lymphocytic leukemia who are in complete or partial remission after two or more lines of prior therapy.
The FDA recently expanded the drug label for carfilzomib (Kyprolis), which is now approved in combination with dexamethasone or with lenalidomide plus dexamethasone for patients with relapsed or refractory disease who have received one to three lines of therapy.
A laboratory study found that the Hhex protein is overexpressed in acute myeloid leukemia cells and is necessary for their propagation but not for normal myelopoiesis.
The FDA approved the proteasome inhibitor ixazomib, in combination with lenalidomide and dexamethasone, to be used as a second-line treatment in multiple myeloma.
The antibody-drug conjugate brentuximab vedotin is effective as a frontline therapy for Hodgkin lymphoma patients over age 60 who are unfit for chemotherapy.
The FDA recently granted priority review status to ixazomib (Takeda) for the treatment of relapsed or refractory multiple myeloma.
Treatment with a short course of vemurafenib was effective and rapid in patients with relapsed or refractory hairy-cell leukemia, resulting in overall response rates of over 95%.
Combined treatment with lenalidomide/rituximab resulted in better clinical response in patients with recurrent follicular lymphoma than did lenalidomide alone.
Daratumumab, a monoclonal antibody that targets CD38, was safe and effective in patients with heavily pretreated and refractory multiple myeloma.